TACR1 and intestinal motility disease: According to the data obtained from animal experiments, cell cultures, and clinical studies, it seems that NK-1 receptor antagonists should be effective in the treatment of affective and anxiety disorders, pain syndromes, intestinal motility disorders, and cancer.